<SEC-DOCUMENT>0000950170-25-069147.txt : 20250512
<SEC-HEADER>0000950170-25-069147.hdr.sgml : 20250512
<ACCEPTANCE-DATETIME>20250512160457
ACCESSION NUMBER:		0000950170-25-069147
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250512
DATE AS OF CHANGE:		20250512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neumora Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001885522
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				844367680
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41802
		FILM NUMBER:		25934663

	BUSINESS ADDRESS:	
		STREET 1:		490 ARSENAL WAY, SUITE 200
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		(857) 760-0900

	MAIL ADDRESS:	
		STREET 1:		490 ARSENAL WAY, SUITE 200
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RBNC Therapeutics, Inc.
		DATE OF NAME CHANGE:	20210929
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nmra-20250512.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-12T10:42:11.8340+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:nmra="http://www.neumoratx.com/20250512" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_8e5f111f-2395-404b-a290-149cccdf0cc9" name="dei:AmendmentFlag" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655">false</ix:nonNumeric><ix:nonNumeric id="F_950baf06-41bc-4f73-992d-e56609d72a21" name="dei:EntityCentralIndexKey" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655">0001885522</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="nmra-20250512.xsd"/></ix:references><ix:resources><xbrli:context id="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001885522</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-12</xbrli:startDate><xbrli:endDate>2025-05-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:216pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:3in;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ccfc93b-8caa-4d7a-a9e5-09ab84ac1095" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:216pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:3in;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:100%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_3004ef69-ed69-4eb8-90a8-76522caeb838" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">May 12, 2025</span></ix:nonNumeric></span></p></td>
     </tr>
    </table><p style="margin-left:216pt;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:3in;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d38ea17-5fae-4b09-a747-77a3d5e46de0" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neumora Therapeutics, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:216pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:3in;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:20%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:20%;box-sizing:content-box;"/>
      <td style="width:18%;box-sizing:content-box;"/>
      <td style="width:41%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0eff4dd9-fe6c-444d-9628-8c6aae65727d" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0d186697-baa2-4f52-82e0-69adcff1ee4f" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-41802</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f9d4ae78-674f-419c-8d80-f115eb3f5fd1" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">84-4367680</span></ix:nonNumeric></span></p></td>
     </tr>
     <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a538c6c8-081b-467f-9d9a-9a7773cdaeec" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">490 Arsenal Way, Suite 200</span></ix:nonNumeric></span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4465f222-45ae-4095-a682-71d915144be4" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Watertown</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_d6d1b04b-2bb9-466c-8e43-dad7bf2d0c3f" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_80950434-4062-47fd-83b5-a23d2c651d01" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">02472</span></ix:nonNumeric></span></p></td>
     </tr>
     <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:100%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_3586434e-1af6-442b-989b-9414cd57d418" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">857</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_31d18891-7c22-426f-a10d-f5ffb2733ba7" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">760-0900</span></ix:nonNumeric></span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:100%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9bd2c0fc-c32c-4cc2-8518-d17863a28e16" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Not applicable</span></ix:nonNumeric></span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:216pt;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:3in;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_875b99a8-deb5-441a-a02f-80a082531998" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c84917f-8f6e-4ac7-ac48-65a94b210607" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3b9df4c-6f6e-4393-a6e2-f4d1fb462416" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0984235d-9187-4acc-beef-63dfbe349b0c" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:38%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:15%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:45%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d2718cc9-2cca-4a41-a6ff-c4e79506623f" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a4ab6e8c-73de-4e47-9431-a7acfb329714" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NMRA</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8a9e873e-233f-4efd-b935-4beb585e2bdd" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_3a3716a0-5ccc-42f6-b2ff-6f5888e52e4f" contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 12, 2025, Neumora Therapeutics, Inc. (&#8220;Neumora&#8221; or the &#8220;Company&#8221;) announced its financial results for the first quarter ended March 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information furnished pursuant to this Item 2.02 of this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></h2>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:14%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:85%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit Number</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Description</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nmra-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release dated May 12, 2025</span></a></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:6%;box-sizing:content-box;"/>
      <td style="width:44%;box-sizing:content-box;"/>
      <td style="width:4%;box-sizing:content-box;"/>
      <td style="width:46%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">NEUMORA THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 12, 2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael Milligan</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Milligan<br/>Chief Financial Officer</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nmra-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.3in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><img src="img49001591_0.jpg" alt="img49001591_0.jpg" style="width:144px;height:31px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">On track to report topline data from NMRA-511 in Alzheimer&#x2019;s disease agitation around the end of 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">                                            </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 2025; cash runway extended into 2027</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company to host conference call today at 4:30 p.m. ET</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WATERTOWN, Mass., May 12, 2025 &#x2013;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neumora Therapeutics, Inc. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Our vision in building Neumora is to make a difference for people living with brain diseases. With our diverse, industry-leading pipeline, multiple upcoming clinical catalysts, experienced team and strong financial foundation, we are making important progress towards achieving that goal,&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">said Paul L. Berns, chairman and chief executive officer, Neumora. &#x201c;We are advancing enrollment for the Phase 1b signal-seeking study of NMRA-511 in Alzheimer&#x2019;s disease agitation, have taken important steps to help optimize the navacaprant program in major depressive disorder, and expect to bring an M4 PAM into the clinic in the coming months. I envision that this will be a productive year with updates across several programs in our portfolio, and we look forward to sharing more in the coming quarters.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KEY PIPELINE HIGHLIGHTS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neumora is advancing a therapeutic pipeline of seven neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Navacaprant (NMRA-140): Optimized KOASTAL-2 and -3 Phase 3 Studies Enrolling; Data Expected in 2026</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects to report topline data from KOASTAL-3 in the first quarter of 2026 and KOASTAL-2 in the second quarter of 2026.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Company today announced the </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publication of data</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the randomized, double-blind, Phase 2 clinical trial of navacaprant in major depressive disorder in the </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Journal of Clinical Psychopharmacology.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the study, navacaprant monotherapy demonstrated statistically significant and clinically meaningful reductions in symptoms of depression and anhedonia in participants with moderate-to-severe major depressive disorder.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NMRA-511: On Track to Report Data from Phase 1b Study in Alzheimer&#x2019;s Disease (AD) Agitation Around the End of 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neumora is advancing a Phase 1b signal-seeking study evaluating NMRA-511 initially in healthy elderly adult participants in Part A and then people with agitation associated with dementia due to AD in Part B. The Company is on track to report data around the end of 2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.3in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">M4 Positive Allosteric Modulator (PAM) Franchise: Progress M4 PAM Program into the Clinic in Mid-2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neumora&#x2019;s M4 franchise comprises multiple novel compounds. Each compound has different properties and chemical composition, has demonstrated robust activity in preclinical efficacy models and shown high selectivity for the M4 receptor. The Company plans to progress an M4 program into the clinic in mid-2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KEY BUSINESS UPDATES</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neumora today announced that it has entered into a venture debt facility for up to $125 million with K2 HealthVentures, an alternative investment firm that provides flexible, long-term financing solutions in the life sciences and healthcare industries. Under the terms of the facility, $20 million was drawn at closing, with an additional $20 million available to be drawn at Neumora&#x2019;s option by December 31, 2025. The additional $85 million will be available for drawdown at Neumora's option upon the achievement of certain milestones.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;We are pleased to announce a strategic financing transaction with K2 HealthVentures, a trusted partner to many of the world&#x2019;s most innovative biopharmaceutical companies,&#x201d; said Michael Milligan, chief financial officer, Neumora. &#x201c;This infusion of flexible, non-dilutive capital bolsters our strong financial position, expanding our ability to advance multiple ongoing clinical development programs and commercial planning for navacaprant.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;We are excited to partner with Neumora in support of their efforts to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed,&#x201d; said Nimesh Shah, managing director at K2 HealthVentures. &#x201c;Neumora is advancing a potentially industry-leading pipeline targeting a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. We look forward to contributing to their success through this transaction.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $20 million in non-dilutive capital from this facility drawn to date, combined with the cash already on the Company&#x2019;s balance sheet, further strengthens its financial position and will support operations into 2027.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leerink Partners served as exclusive financial advisor to Neumora on the transaction.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FIRST QUARTER 2025 FINANCIAL RESULTS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Position:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of March 31, 2025, Neumora had cash, cash equivalents and marketable securities of $249.4 million.</font></div></div><p style="margin-left:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Guidance: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects that its cash, cash equivalents and marketable securities as of March 31, 2025 and the $20 million drawn at the close of the K2 HealthVentures transaction will enable it to fund its operating plan into 2027.</font></div></div><p style="margin-left:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R&amp;D Expense: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses for the first quarter of 2025 were $52.2 million, as compared to $45.8 million for the same period in 2024. This increase was primarily due to the final $6.3 million of costs incurred under the Amgen Collaboration Agreement.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">G&amp;A Expense:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> General and administrative expenses for the first quarter of 2025 were $18.8 million, as compared to $14.3 million for the same period in 2024. This increase was primarily due to personnel-related costs, including severance pay, one-time bonus payments for key executives and stock-based compensation.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company reported a net loss of $68.0 million for the first quarter of 2025, as compared to $53.7 million for the same period in 2024. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.3in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conference Call Information</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neumora will host a live conference call and webcast at 4:30 p.m. ET today to review these updates. A live webcast of the event will be available on the events and presentations section of the Company&#x2019;s website at </font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">www.neumoratx.com</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Participants may register for the conference call </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">here</font><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and are advised to do so at least 10 minutes prior to joining the call.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About Neumora</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora&#x2019;s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements about Neumora Therapeutics, Inc. (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) within the meaning of the federal securities laws, including statements related to: Neumora&#x2019;s intention to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases; the timing, progress and plans for its therapeutic development programs, including the timing of patient enrollment, initiation and data read outs for its programs and studies, including for the KOASTAL-2 and -3 studies, and the Phase 1b signal seeking study evaluating NMRA-511, as well as its clinical trial and development plans; timing and expectations related to regulatory filings; expectations and projections regarding future operating results and financial performance, including the sufficiency of its cash resources and expectation of the timing of its cash runway; changes to and optimization of the KOASTAL-2 and -3 studies; the potential for Neumora to advance other compounds in its M4 portfolio; expectations regarding appropriate patients being enrolled in the KOASTAL program;  and other statements identified by words such as &#x201c;could,&#x201d; &#x201c;expects,&#x201d; &#x201c;intends,&#x201d; &#x201c;may,&#x201d; &#x201c;plans,&#x201d; &#x201c;potential,&#x201d; &#x201c;should,&#x201d; &#x201c;will,&#x201d; &#x201c;would,&#x201d; or similar expressions and the negatives of those terms. Other than statements of historical facts, all statements contained in this press release, are forward-looking statements within the meaning of the &#34;safe harbor&#34; provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause the actual results or to be materially different from the information expressed or implied by these forward-looking statements, including, among others: the risks related to the inherent uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals; risks related to the timely initiation and enrollment in our clinical trials; risks related to our reliance on third parties, including contract research organizations; risks related to serious or undesirable side effects of our therapeutic candidates; risks related to our ability to utilize and protect our intellectual property rights; and other matters that could affect sufficiency of capital resources to fund operations. For a detailed discussion of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Neumora&#x2019;s business in general, please refer to the risk factors identified in the Company&#x2019;s filings with the Securities and Exchange Commission (SEC), including but not limited to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 which was filed with the SEC on or about the date hereof. Forward-looking statements speak only as of the date hereof, and, except as required by law, Neumora undertakes no obligation to update or revise these forward-looking statements. Our results for the quarter ended, March 31, 2025 are not necessarily indicative of our operating results for any future periods.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"><br> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.3in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="condensed_operations_and_com_loss_1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Tables</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEUMORA THERAPEUTICS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unaudited Consolidated Statements of Operations and Comprehensive Loss</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except per share amounts)</font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:60.128%;box-sizing:content-box;"></td>
      <td style="width:1.96%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:15.977%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:1.96%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:15.977%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br>March 31,</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,151</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,757</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,785</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,317</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,936</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,074</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(70,936</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(60,074</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense):</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,074</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,365</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense), net</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(25</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,049</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,353</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss before income taxes</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(67,887</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(53,721</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(67,992</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(53,721</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on marketable securities</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(65</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(72</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(68,057</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(53,793</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.42</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.34</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">)</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares outstanding, basic and diluted</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161,451</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,943</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unaudited Condensed Consolidated Balance Sheets</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:67.393%;box-sizing:content-box;"></td>
      <td style="width:1.6%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:12.703000000000001%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:1.6%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:12.703000000000001%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br>2025</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br>2024</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and marketable securities</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249,353</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">307,578</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256,748</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">316,972</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,384</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,908</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#x2019; equity</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228,364</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-kerning:none;min-width:fit-content;">$</font></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">287,064</font></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neumora Contact</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Helen Rubinstein</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">617-402-5700</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Helen.Rubinstein@neumoratx.com</font><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></font><font style=""></font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img49001591_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img49001591_0.jpg
M_]C_X  02D9)1@ ! @$!( $@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !> ; # 2(  A$! Q$!_\0
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MC]6Q%.JZCHR4:=>,%'VD4[\WT7 .4\4^(7AWC,#XSY5A\1/-<96J8"A7P=#
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MTY\L;1<I6=MW?4****\8^C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*]E\6?\ !J]_R>3\<?\ LW^Z_P#4X\*U_>17\&__  :O?\GD_''_ +-_NO\
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MT:TN%8V>H>(&N;RRTCPCI5V5+6]UKU_;7=["&FTK3M25& _SN/VWOV&_CO\
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MNXS25XRM^YG[ =A)9?LU>&)9%*C4=>\77T61C,8U^[L0?<%[)\'N*^T*\?\
M@!X0D\"?!?X;>%YXEAN].\*Z9)J$:@@+J6HQ'4]1&#R,7MY."#R#U).2?8*_
M2.'L++ Y#DV$FG&IA\KP-*I%[JK'#4U47RGS+=G]%< 995R7@;@_*:\7#$9?
MPUDN%Q$'HX8BEEV'CB(M=.6MSJWD%?RJ?\'6O_)LG[,/_9<?$'_J"WM?U5U_
M*I_P=:_\FR?LP_\ 9<?$'_J"WM?9<._\CK ?]?*G_IFJ=/&'_)-YI_UZH_\
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M"RQ?$\<9C\*\/B50K4YU,5["C651*/M,;.<*;FIV:BXQE+FM=Z_C/_P="_\
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M_L*_#+0;:9X[#Q)^T#H']I1*<+.-'\'^+[RT60?Q*D\AD"]-ZJV,J"/YM_\
M@W]^#6L?%O\ X*=? _4K.SGET7X0VGB_XM>)[Z.)GATZRT#PY?Z3HS3/C8C7
MOBW7_#VGQJS*S"YDD0,(7 _HJ_X.G?\ DS#X)?\ 9P-M_P"H+XKK[3,Y0EQ3
MD\$TY4Z<')?RR<Z\X7\]%*W9I]3\VR.%2' W$51IQC5KU%![<T52PD)V[Q;;
M@^CM)=&?B-_P;-^#=#\3?\%'EUO5K2*ZO/ ?P2^(WB7P^9HTD6TU>[G\.^%C
M>('!V3Q:7XBU.*&1?FC,[,N&PP_T,*_S^O\ @U[_ .4@OC+_ +-T\>?^I5X
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MAB>&FJ5:+Y*>5X*O.O@,!62;IO'9[C%.OC*49.5/!O$4U4G#"47/ZP  & ,
M< #H!Z4445_09_?85_*U_P '5]O<7/[,W[,26\$L[#XX>(6*Q1O(0/\ A!;P
M9.T'&2>,XSSC.#C^J6L;6O#GA[Q'%!;^(=!T;7H+:4SVT.M:78ZI%;S,C1M-
M!'?03I%*8V:,R1JKE&92=I(KNRW&+ 8W#XMTW55"4I>S4N1RYH2A;FY96^*_
MPO:QYF<Y<\VRS%Y>JJH/$PA%57#VBAR5:=2_(I0YK\EK<RWO?2Q_ Q_P;!V5
MY;?\%"?%S7%I<PJ?V<?B  \D$J)D^+/AX0I<H$#, 2JE@6"MM!VMC_0 KFM(
M\%^#O#]TU]H'A/PUH=Z\+6[W>D:%I>FW3P.RN\#7%E:P2M"SHC-&7*,R*Q4E
M01TM;9OF*S3&/%JBZ"=.G3Y'/VGP)J_-R0WOMRZ=SFX>R=Y'ERP$L0L2U6JU
M?:JDZ2_><ON\CJ5-N7?FUOLADL4<T<D,T:2PRH\4L4J+)'+'(I5XY$8%71U)
M5T8%64D$$$BO\[O_ (+O_P#!+FZ_8P^/!^-'P?\ #<Z_LV_';6M1U#1[/2[5
MWT_X8_$";?J.N> 9$C#?8M'OP;C7/!2L$@&F#4-$MQCP^3+_ *(]9FK:)HVO
MVGV#7=(TS6K'S4F^Q:M86NI6GG1;O+F^S7D4T/FQ[FV2;-Z;FVD9-/*,UK93
MB?;0C[2E.+A6H.7*JD=XM.TE&<):QGRMI.4=I,GB#(</G^"6'JR]C7I2]IAL
M2H<\J,G933CS1<Z=2*M.'-&[4)WYH(_A3_X-9;.[MOVR/C>UQ:W$"M\ +L*T
ML,B*2/&_A4XW,H4,1D@$@D D [3C^VSXW?!?X=?M$?"CQU\%?BQH$'B;X??$
M30+OP]XCTF4^7(]M<A7@O;"Y"L]CJVEWD=MJ>D:A$#-8:E:6MW%EX0#V&C^#
MO"/AVXEN_#_A7PYH5U-%Y$USH^AZ9IEQ+!N#^3+-96L$DD6\!_+=BFX!L9 -
M='1FN9O,<>\=3IRPTN6BHQ53GE"5&*49J:C#6Z4E9*SZCR/)8Y1E2RRK5AC(
M.5=U).C[.%2%=OFIRI2G53CRMQE>34DW=6/\U;_@HY_P12_:D_86\5Z]XC\+
M^&?$7QJ_9T:]N;GPW\5_!^CW&IWNA:5)*6M-/^)>A:5%<7?A;5;2)TM[C5S
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M2=<LWT[6]+T[6-/E9'DL=5LK;4+.1XF#QN]K=Q30.T;@,C,A*, RD'FL;2_
MO@C0[V/4M%\&^%=(U&)9$BO]+\/:1I][$DJ[)4CNK2SAG195^615D =?E8$<
M5E@<\6#RK%9:\,ZCQ/M[5E545#VU*-/^'[.7-R\M_C5[VTW-LSX8EF&?8#.E
MC(TE@GA&\.Z#FZGU7$2KZ5?:Q4.?FY?X<N6U]=CJJ9+%'/')#-&DT,R/%+%*
MBR1RQR*4DCDC<%71U)5T8%64D$$$BGT5\^?6G\'_ /P6+_X(/_$_X/\ CSQA
M^T=^QQX'U/X@_ SQ3J&I>)O%7PO\)VD^I^+OA!J-Y)-?ZK_8N@6ZRZAKWP\:
M9IKC3CI,5W?^%H&.GWMF-(M;?45_GF^%_P >/VAOV<M9O[CX0_%;XK?!K6W=
MH-57P1XN\3^"KN650BM'J5OI-]IYFFC5$3;>1/)&H"@*I(/^NS7A7CC]E[]F
MWXF:G)K7Q#^ 7P;\;:U-.;J?6?$_PV\(:SJUQ<$Y,USJ=]I$U]<.QY8S3R9/
M)R:^QP'%M2CAXX;'X58R,$HJKSI3G"-K1JPG&<*C5OC]UO1R4I7D_P ZS3@&
ME7Q<L9E.->72G-U)4>24J<)MW;P\Z=2G4HQ;N_9VG%7Y8.$$H+_,/\.I^WU_
MP4A^(V@_#ZT\0?'S]I_QE<W$5O96OB/Q1XK\8Z;H$6X"34]5U'7M0N-$\+:7
M9QRF6]U;4;C3[2W@),MP 54^M_\ !3/_ ()^R_\ !/KQY\$?@U<ZK<>+O'^N
M? S0?B!\4]:L$GD\/IXWU[Q-XJM+O1/#.Z)&DT;0+#2K#38;V9(;G5)HIM3F
MM;07<=O'_IL^"_AW\/\ X;::^C?#OP-X/\!Z1(Z22:7X-\-:-X8T^62-2D<D
MMGHEE96\DB(2JR/&S@$@-R<W-8\&>#_$-RE[K_A3PUKEY%"+>.[UC0M+U.YC
M@#,X@2>]M9Y4A#LSB-7"!F9@N22;_P!<)QQ%-TL%&G@Z49KZO"HH2G*44HRE
M-4N2,8:M0C3U;O*3:5L_^(>0GA*T:^93K9C6G2?URI1E.%*G"2E*$:<J_/.=
M1)1E5G5;4?=C!)RYOYJ_^#62">W_ &.?CHEQ!- Q_: D(6:*2(L/^$#\+C<F
M]5WJ#E2RY 8%2=RD#^GFLC1_#^@^';>2U\/Z)I&A6LTIGEMM'TVRTRWEF*A3
M-)#90P1O*555,C*7VJ!G  K7KY?,,6L=C<1BU3]DJ\^?V;ES\ONQC;FY8WVO
M?E6Y]OE& >5Y;A,O=55WA:7L_:J'LU/WI23Y.:?+I*UN9[7\@KS?XJ_"OPE\
M8O!VH^#/%]GY]C>*9+.]A"+J&CZBB.MOJ>G3,K".X@+LKHP:"Z@>6UN8Y;>:
M2-O2**\W$8>ABJ%7#8FE"OAZ].5*M1J14J=2G-.,H2B]&FG;\5J;X_ 8+-,%
MBLNS'"T<;@,=0J8;%X3$TXU:&(P]:+A4I5:<DU*,XMIK=;III-?S4_'[]G#Q
MW\ O$;6FL6LU_P"';R>8Z!XJLH)3IFI0IEQ&T@WBSU"*+FXTVX<7$85Y(C<V
M@%T_L7[/G[='C[X1V]IX:\5Q2^._!5OLBM[*\NO*UG1K8!5$6C:FZ2$P1X)C
MTW4!-:*#Y5K/IL0%?NQXC\->'_%^C7OA[Q1H^GZ[HFHQ-#>Z;J=M'=6LZ$$
ME) =DJ$[HIHRDT+@212(ZJP_,+XO?\$V]*O;JZUGX4>*H-$MG$DS>'?%/VRX
MM[=V,>U+37+."]O#;*?-Q'>Z==W8W(9-0FVD'\0S;@;/>%L94SG@_&5/JZNY
MX:5:E#$4*3:;I5/K+CAL=A4]HU7[6/NWA5G'VS_BGBOP2XX\,<YK<8^$6;UO
MJ$.:=;+JF,P]#'8'#.:G/"XA9A.&7YWE<9)<D,4WBH6IJ5'$UJ;Q;\D_:A_;
MKTGXN>!9/A[X \.:SH^F:Q-9S^(M4\0O81WL\5A<17UMIMC9Z9>:A D!OH+>
MYN;R>\$KBV2VCLT25YT\Y_8!^'6H^+_CII/B1;>;^Q_ 4%SX@U&] (ACN);.
M\TW2K,L?E:>\O;HS11\EK?3[Z08,&:]'\"?\$V_'.K:BA\7>.?".G:5$\37#
M: VM:S>R1;P)4C@O]'\/PHY7<(W:[*JVUVC=<QG]9/A+\(?!/P6\*0>$O!.G
M?9;42?:M2U"X*2ZIK6H%%C>_U.Y5(Q++L58H(8TBM;.W5+>T@AB7:5P_P_Q'
MQ5Q!@^).(Y4X8; 3H3I\LL/>M+"3]MA\-0H8>4U2I1KR=6O.KRRE>48<[GS4
MYX#X#\1?%#C_ "GQ$\1*F'HY;D-?!5<.H5<OYL7/*JSQ>!R[!8++ZM:.&PL,
M;-XK&5L4X5*BG4A3]K.KST?$OVX? &J>/_V?_$,6BP276I>%=0L/&$=I$C22
MW-GID-Y9:NL4:!G>2#1]3O[U$0%I&M0B@LP!_$;X"?&+5?@1\2=*\<6.G0ZF
MEF+FPU;2KAS;F^TN]C,%]:QW0CE:UGP$GAF$4BK<VT!ECDB#HW].C*K*RLH9
M6!5E8 JRD8*L#D$$$@@C!'!K\UOCM_P3S\-^-=6OO%/PRUNT\&WUXTMU>^']
M1MY9- :X*RN[Z;/9QRW6EQ2R,C/:M:ZA!$$*6:VL3+$GN<?\*YMB<QP?$^0R
MB\=@:=%5J3J4J52+PM657#XJC*NXT9N'.XUJ5224H0ARQFW.+^X\>/"[BG,\
M_P G\2^!*L'G>24<)'%X5XC"X:O"668BIBL!F>$GC90P=:5)U94L7A<14C&I
M2IT>2%;FK4WQ/Q"_X*::5)H!M_ACX'U2V\174!5M2\7OI[V&E2O&1OM=/TF_
MNGU22-R"C7ESIL*[0\EO< M /S!\0>(_'_QF\9OJ6L7>K^+?%GB"ZAMH5Q->
M7<\C,5M;&RM8$;9%%O9;6QLH$BCW.MM;IO*G[>\)_P#!-[XBZIJI@U_QMX(T
M_3HG#23Z3-KVK7;1+(@8+:7>@Z)$69"P ^W(%;!W$9K]./@C^S#\+O@7:I+X
M;TO^U/$S0F&[\7ZTD-QK$BN%$T-@%1;?2+20J-\%BB2S@*+VYNV57'R]'(^-
MN/*]*6=XR.$RS#RCS-3PWLHR2M)X? X2<E4Q+5_WN)E",%)J%1Q7LW^883@G
MQH\<\;AJG&>;TLKX:P-6*G*-7+_JT*D%RU'@LFRJM*.(S"2YK8K,94H4HSDJ
M5=P7U>7SK^Q]^QI%\*Q9_$;XDV]O>>/Y8A+HNAGR[BU\()*G_'Q<."\5QXB:
M-F3?$SV^E([QV\DUTSW,?Z)445^V9+DN7Y!@*>7Y=1]E1A[TYR?-6Q%:22G7
MKU++GJSY5=V48Q4:=.,*<(0C_:'!O!N0\"9%AN'^'L)]7P="]2M5J-5,7CL7
M.,8UL;CJ_+%U\36Y(J4N6-.G3C3H4*=*A2I4H%%%%>L?5!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
;%%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>nmra-20250512.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-12T10:42:12.1981+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.neumoratx.com/20250512" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nmra="http://www.neumoratx.com/20250512" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="nmra-20250512.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>May 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 12,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Neumora Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001885522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-4367680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">490 Arsenal Way, Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">760-0900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Not applicable<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NMRA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )R K%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( )R K%H9D? ][P   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%.PS ,AE\%Y=XZ[>@.49<+B-,F(3$)Q"U*
MO"VB::+$J-W;TX:M$X('X!C[S^?/DEL=A/81GZ,/&,EBNAM=UR>APX:=B((
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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MJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%
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M?^:+X3]>?P%02P$"% ,4    " "<@*Q:1L=-2)4   #-    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )R K%H9D? ]
M[P   "L"   1              "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( )R K%J97)PC$ 8  )PG   3              "  >$!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ G("L6A.CXRR&!   7!$
M !@              ("!(@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    ( )R K%J?H!OPL0(  .(,   -              "  =X,  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ G("L6I>*NQS     $P(   L
M         ( !N@\  %]R96QS+RYR96QS4$L! A0#%     @ G("L6CJJHN=
M 0  / (   \              ( !HQ   'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( )R K%HD'INBK0   /@!   :              "  1 2  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( )R K%IED'F2&0$
M ,\#   3              "  ?42  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     )  D /@(  #\4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nmra-20250512.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="nmra-20250512.htm">nmra-20250512.htm</File>
    <File>nmra-20250512.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nmra-20250512.htm": {
   "nsprefix": "nmra",
   "nsuri": "http://www.neumoratx.com/20250512",
   "dts": {
    "inline": {
     "local": [
      "nmra-20250512.htm"
     ]
    },
    "schema": {
     "local": [
      "nmra-20250512.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_f3b658ff-c80b-48f3-88fa-72d8567e8655",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250512.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f3b658ff-c80b-48f3-88fa-72d8567e8655",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nmra-20250512.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.neumoratx.com/20250512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-25-069147-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-069147-xbrl.zip
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M2-:"OI.$QS&?H,]10A(:D1CUJE[W8)BT@0[C&'5EM0QU><;%)6>-HM%^#O
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MG5&>HAZGRL>EFR@52+=WV7N4ABCO<_EI)$"]A5Z.QK1/D@LN_6SRL^Z;U@Q
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MQ\B_A2[RIM!$724C!:/ )13ZLU &+U<_-=H*@+Y/[6'@HVM"W2LT@H'C=Y4
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MZ56>)Z\R7\W-]>GF>G-NVV.FI-4H1P\_6FYNE8D[#,1UTY>)(/48F@VR,#H
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M_VQL%A'KH)AU=:U?[N.H^ KM75-S#'0TB;?5P&M3S^:WPOXIO.+= KN&&15
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-  , NP   )4\      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>nmra-20250512_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nmra-20250512.xsd" xlink:type="simple"/>
    <context id="C_f3b658ff-c80b-48f3-88fa-72d8567e8655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001885522</identifier>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_8e5f111f-2395-404b-a290-149cccdf0cc9">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_950baf06-41bc-4f73-992d-e56609d72a21">0001885522</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_6ccfc93b-8caa-4d7a-a9e5-09ab84ac1095">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_3004ef69-ed69-4eb8-90a8-76522caeb838">2025-05-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_5d38ea17-5fae-4b09-a747-77a3d5e46de0">Neumora Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_0eff4dd9-fe6c-444d-9628-8c6aae65727d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_0d186697-baa2-4f52-82e0-69adcff1ee4f">001-41802</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_f9d4ae78-674f-419c-8d80-f115eb3f5fd1">84-4367680</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_a538c6c8-081b-467f-9d9a-9a7773cdaeec">490 Arsenal Way, Suite 200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_4465f222-45ae-4095-a682-71d915144be4">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_d6d1b04b-2bb9-466c-8e43-dad7bf2d0c3f">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_80950434-4062-47fd-83b5-a23d2c651d01">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_3586434e-1af6-442b-989b-9414cd57d418">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_31d18891-7c22-426f-a10d-f5ffb2733ba7">760-0900</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_9bd2c0fc-c32c-4cc2-8518-d17863a28e16">Not applicable</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_875b99a8-deb5-441a-a02f-80a082531998">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_4c84917f-8f6e-4ac7-ac48-65a94b210607">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_b3b9df4c-6f6e-4393-a6e2-f4d1fb462416">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_0984235d-9187-4acc-beef-63dfbe349b0c">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_d2718cc9-2cca-4a41-a6ff-c4e79506623f">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_a4ab6e8c-73de-4e47-9431-a7acfb329714">NMRA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_8a9e873e-233f-4efd-b935-4beb585e2bdd">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_f3b658ff-c80b-48f3-88fa-72d8567e8655"
      id="F_3a3716a0-5ccc-42f6-b2ff-6f5888e52e4f">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
